Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-419-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.52 million
Profitability
Miscellaneous
Employees38
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03. The firm earned $0.38 million during the quarter, compared to analyst estimates of $0.39 million. Syndax Pharmaceuticals had a negative net margin of 4,310.68% and a negative return on equity of 108.44%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
7 equities research analysts have issued 1-year price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $5.00 to $19.00. On average, they expect Syndax Pharmaceuticals' share price to reach $14.00 in the next year. This suggests a possible upside of 115.7% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
What are Wall Street analysts saying about Syndax Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (10/12/2019)
- 2. Nomura analysts commented, "Trial Design, Details, Market Opportunity, and Biology p.4-6. The Ph1/2 trial outline for SNDX-5613 (the clinical program is now called AUGMENT) was disclosed on the earnings call presentation; the IND was cleared on July 10 (note here). The Ph1 portion will not select pt for mutations (per FDA request), but will begin with BID doses at an estimated efficacious dose (based on preclinical data). Possible issues may arise with PK due to the need for continuous drug exposure; expected tox based on preclinical experiments has not been published but will be announced at an upcoming medical meeting (ASH?). Ph2 expansion will use a yet-to-be disclosed biomarker to assess PD. SNDX-6352 in cGVHD RP2D Data Delayed (Now 2H20E vs. 3Q19E); Pts Available." (8/11/2019)
Has Syndax Pharmaceuticals been receiving favorable news coverage?
News stories about SNDX stock have trended very negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Syndax Pharmaceuticals.
Are investors shorting Syndax Pharmaceuticals?
Syndax Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 700,600 shares, an increase of 23.4% from the August 30th total of 567,700 shares. Based on an average daily trading volume, of 152,700 shares, the short-interest ratio is presently 4.6 days. Currently, 3.2% of the shares of the stock are sold short. View Syndax Pharmaceuticals' Current Options Chain.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Principia Biopharma (PRNB), Stoke Therapeutics (STOK), Wave Life Sciences (WVE), Organogenesis (ORGO), Revance Therapeutics (RVNC), Karyopharm Therapeutics (KPTI), Rocket Pharmaceuticals (RCKT), Kura Oncology (KURA), Cytokinetics (CYTK), Emisphere Technologies (EMIS), ZIOPHARM Oncology (ZIOP), Vectura Group (VEGPF), NextCure (NXTC), Akero Therapeutics (AKRO) and Akorn (AKRX).
What other stocks do shareholders of Syndax Pharmaceuticals own?
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)
- Mr. Michael A. Metzger, Pres & COO (Age 48)
- Mr. Richard P. Shea, CFO & Treasurer (Age 67)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $6.49.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $176.12 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.
What is Syndax Pharmaceuticals' official website?
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
